Pioneers in Immunoregulatory Drug Discovery and Development
We develop novel immunoregulatory therapeutics for patients with autoimmune diseases, starting with ulcerative colitis and Crohn’s disease.
Our Mission
Our management team has significant public and private biotech company experience in the development of immunoregulatory drugs and a proven track record in raising capital, IPO and M&A for effectively accelerating drug candidates into and through late-stage clinical development. We are on a mission to develop safer and more effective therapeutics that address the unmet needs of patients with inflammatory and autoimmune diseases.
Press and Articles from NImmune
NImmune Biopharma Acquires Development and Commercialization Rights to Omilancor in Asian Markets
Download Press Release Transaction is highly shareholder value accretive, enabling the potential acceleration of the global registration directed Phase 3 program in ulcerative colitis, the Phase 2 program in Crohn’s disease, and additional I&I indications...
The NIMML Institute and NImmune Biopharma Announce Publication of New Mechanistic Insights on the Immunometabolic Control of Systemic Lupus Erythematosus in the Journal of Immunology
Download Press Release NIM-1324 validated as the first LANCL2 drug with therapeutic efficacy in systemic inflammation in three mouse models of lupus to support immune tolerance A mechanism of LANCL2 newly discovered in phagocytes that combines with established...
NImmune Biopharma to Participate in UBS Virtual Biotechnology Private Company
Download Press Release BLACKSBURG, VA. – September 16, 2024 – NImmune Biopharma ("NImmune”), a Phase 3 precision inflammation & immunology (I&I) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics...
NImmune Leadership Team
A highly experienced and talented team with deep knowledge of LANCL therapeutics and a proven track record of biotech industry success.
Product Candidates
NImmune’s clinical development pipeline includes first- and best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases with multiple catalyst milestones in the next 12 months. Lead clinical candidate omilancor, an oral, once-daily, gut-restricted, first-in-class LANCL2 therapeutic is in Phase 3 clinical development for ulcerative colitis and Phase 2 clinical development for Crohn’s disease, with multiple I&I indications planned. Topline Phase 3 data readout expected in 2026.
Learn more about the omilancor story, LANCL2 mechanism of action, and the market opportunity we seek to address.
Contact Us
If you would like to know more about our research, please fill out the form below.